|
R&D Pipeline News Vol. 2, Issue 14: Antibodies in Rheumatoid Arthritis |
|
|
|
11 Apr 2006 |
 |
| |
Featured this week
R&D Pipeline Strategy Biogen Idec
|
Vol. 2 Issue nº 14
April 10, 2006
|
 |
|
|
Featured this week
|
1. Antibodies in Rheumatoid Arthritis
|
- Five approved products (antibodies and fusion proteins)
- Main targets are TNF-alpha and CD20;
- Next generation antibodies for TNF-alpha and CD20 to reduce immunogenicity;
- Most advanced novel target: interleukin-6 receptor;
- BAFF/BLyS attractive target
|
|
|
R&D Pipeline Strategy Biogen Idec
|
1. Near Term Growth
|
- B-cell franchise around rituxan (label expansion);
- Launch of rituxan in rheumatoid arthritis;
- Multiple sclerosis franchise;
- Launch of Tysabri in US and Europe ;
- Upside indications Tysabri (Crohn's disease)
|
2. Mid Term Growth
|
- External growth;
- Licensing deal with PDL BioPharma for three projects;
- Further licensing-in (US$ 200 mln budget) and M&A;
|
3. Long Term Growth
|
- Mix of own projects and partnerships;
- Mixture of gene therapy, small molecules, fusion proteins and therapeutic protein;
- Two primatized antibodies in pipeline
- Indication focus on oncology, neurology and inflammatory diseases
|
|
R&D Pipeline News
Get your Subscription Now
|
R&D Pipeline News is a premier information source about research and development (R&D) projects in the pipeline of the biopharmaceutical industry and is directed to all stakeholders in R&D . R&D Pipeline News covers all relevant treatment modalities, including. drugs, medical devices, biomaterials, combination products, cell therapy and drug delivery products.
Read more about R&D Pipeline NewsOrder Now
 
|
|
|
|
|
|
|
|
| |
|
